Michelle McMurry-Heath is Director at Bioventus Inc. (BVS). They have made 5 open-market trades across 2 companies since 2025, most recently 2026-06-02.
CIK 0001904156
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 5 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| BVS | 77,279 | $1.0M |
| RVTY | 5,248 | $801K |
| PKI | 1,058 | $122K |
| Total | $2.0M |
Shares reported on the most recent Form 4, priced at the 2026-06-04 close.
Counted per filing, not per execution lot — a purchase filled in several tranches is one decision.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| BVS | SELL | 2026-03-11 | 2026-03-13 | $8.79 | $105K | +5.0% | +8.1% | -0.6% |
| RVTY | SELL | 2026-02-23 | 2026-02-25 | $97.26 | $58K | -5.6% | -14.0% | -0.8% |
| BVS | SELL | 2025-11-07 | 2025-11-10 | $7.42 | $263K | -12.8% | +0.1% | +13.8% |
| RVTY | SELL | 2025-05-29 | 2025-05-30 | $92.17 | $55K | +7.3% | +8.0% | -0.3% |
| RVTY | SELL | 2025-02-06 | 2025-02-07 | $119.49 | $471K | -2.6% | +0.3% | -21.2% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.